Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification

Fig. 1

Schematic integration of molecular subtyping of triple-negative breast cancer (TNBC). Essential molecular alterations and putative targeted therapies are listed below the subtype. The LAR subtype almost overlaps with MPS1. The BLIS subtype almost overlaps with MPS2 and contains metabolomic C2 and C3 subtypes. MPS1 is highly consistent with the metabolomic C1 subtype

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us